ABSORB China: Long term data published in EuroIntervention
Comparison of everolimus-eluting bioresorbable vascular scaffolds and metallic stents: three-year clinical outcomes from the ABSORB China randomised trial
Few areas in interventional cardiology have generated as much discussion as bioresorbable scaffolds. Within the last 12 months a number of clinical trial reports have shown a concerning signal in terms of an increase in late adverse events after implantation of the ABSORB bioresorbable scaffold. This was a problem not foreseen from preclinical models or early clinical trials. In order to enable further assessment of this issue and quantification of the degree of risk, it is vitally important that investigators of randomized controlled trials with ongoing follow-up publish their outcome data in the peer-reviewed literature at regular intervals and as soon as possible after data analysis. In this respect we are pleased to publish today the updated 3-year follow-up results of ABSORB China.
Figure 2. Time-to-event curves for TLF and its components in the intent-to-treat population. Time-to-event curves up to 1,095 days for target lesion failure (TLF) (A), cardiac death (B), target vessel-related myocardial infarction (TV-MI) (C), and ischaemia-driven target lesion revascularisation (ID-TLR) (D). HR: hazard ratio.